Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 6/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 6/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | SUCNR1 | Q9BXA5 | 3/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131967 | 1.00 | BCL9 (0.48) | BCL9CTNNB1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4138373 | 0.90 | SLC6A2 (0.46) | BCL9CTNNB1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4138369 | 0.90 | SLC6A2 (0.46) | BCL9CTNNB1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4124171 | 0.86 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3KCNH2SUCNR1 | |
| SCHEMBL4124176 | 0.86 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3KCNH2SUCNR1 | |
| SCHEMBL4138033 | 0.85 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3KCNH2SUCNR1 | |
| SCHEMBL4138036 | 0.85 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3KCNH2SUCNR1 | |
| SCHEMBL4126668 | 0.83 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3KCNH2CHRM3 | |
| SCHEMBL4126675 | 0.83 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3KCNH2CHRM3 | |
| SCHEMBL4143744 | 0.82 | KCNH2 (0.51) | BCL9CTNNB1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215857-A1 | Therapeutic Pyrrolidines | PFIZER PRODUCTS INC. (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215857-A1 | Therapeutic Pyrrolidines | OPRL1, HTR5A, OPRD1 | BCL9 1878/4885CTNNB1 3931/4885SLC6A2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.